Trials / Completed
CompletedNCT01791699
Moxonidine for Prevention of Post-ablation AFib Recurrences
Pharmacologic Suppression of Central Sympathetic Activity for Prevention of Atrial Fibrillation Recurrence After Pulmonary Vein Isolation (MOXAF)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Spyridon Deftereos · Academic / Other
- Sex
- All
- Age
- 25 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Hypothesis: Modulation of central nervous sympathetic activation by administration of moxonidine, a centrally acting medication which decreases the sympathetic nervous system activity, can lead to a decrease in atrial fibrillation recurrence after ablation treatment with pulmonary vein isolation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Moxonidine | |
| DRUG | Placebo |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2013-11-01
- Completion
- 2014-04-01
- First posted
- 2013-02-15
- Last updated
- 2014-05-06
Locations
3 sites across 1 country: Greece
Source: ClinicalTrials.gov record NCT01791699. Inclusion in this directory is not an endorsement.